1. "2022"
Formats
  1. Journal Article (2449)
  2. Meeting Abstract (2196)
  3. Review (615)
  4. Editorial (363)
  5. Book Section (139)
  6. Correspondence (117)
  7. Guidelines (112)
  8. Research Letter (82)
  9. Miscellaneous (60)
  10. Conference Paper (29)
  11. Book Whole (6)
Groups
  1. Department of Medicine (2621)
  2. Solid Tumor Oncology Division (1573)
  3. Sloan Kettering Institute Postdocs (1364)
  4. GSK Faculty (1152)
  5. Surgery (1036)
  6. Hematologic Malignancies, Division of (964)

More Groups

People
  1. Miguel-Angel Perales (95)
  2. Alexander Drilon (85)
  3. Saad Usmani (83)
  4. Sergio Giralt (77)
  5. Marc Ladanyi (72)
  6. Gilles Salles (69)

More People

Years
  1. 2022 (6168)
Publications
  1. Journal of Clinical Oncology (520)
  2. Blood (319)
  3. Cancer Research (191)
  4. Annals of Oncology (158)
  5. Annals of Surgical Oncology (134)
  6. International Journal of Radiation Oncology, Biology, Physics (132)

More Publications

Publishers
  1. Elsevier Inc. (794)
  2. American Society of Clinical Oncology (583)
  3. Springer (440)
  4. Nature Publishing Group (379)
  5. American Society of Hematology (369)
  6. Oxford University Press (360)

More Publishers

Results (6168)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinicopathologic and mutational landscape of BRAF(V600E)-mutant non-small cell lung carcinoma
    Meeting Abstract

    Sui, J. S. Y.; Ladanyi, M.; Rudin, C. M.; Drilon, A. E.; Riely, G. J.; Kris, M. G.; Offin, M.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Impact of clonal hematopoiesis on tumor control following radiation therapy
    Meeting Abstract

    Tao, J.; Setton, J.; Vela, P. S.; Safonov, A. M.; Comen, E. A.; Braunstein, L. Z.; Reis-Filho, J. S.; Riaz, N.; Powell, S. N.; Levine, R. L.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Tamibarotene in combination with venetoclax and azacitidine in previously untreated adult patients selected for RARA-positive AML who are ineligible for standard induction therapy (SELECT AML-1)
    Meeting Abstract

    Stein, E.; De Botton, S.; Pigneux, A.; McMahon, C.; Ball, B.; Borthakur, G.; Eghtedar, A.; Kambhampati, S.; Tache, J.; Wang, E. S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Impact of bone marrow involvement in patients with peripheral T-cell lymphoma undergoing autologous stem cell transplant
    Meeting Abstract

    Stuver, R.; Mazloom, A.; Ganesan, N.; Horwitz, S. M.; Moskowitz, A. J.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Association between depth of response (DepOR) and clinical outcomes: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 9ER
    Meeting Abstract

    Suárez, C.; Choueiri, T. K.; Burotto, M.; Powles, T.; Bourlon, M. T.; Shah, A. Y.; Tomita, Y.; Bedke, J.; Zhang, J.; Simsek, B.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRAS(G12C) mutation
    Meeting Abstract

    Spira, A. I.; Riely, G. J.; Gadgeel, S. M.; Heist, R. S.; Ou, S. H. I.; Pacheco, J. M.; Johnson, M. L.; Sabari, J. K.; Leventakos, K.; Yau, E.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Daratumumab (DARA) in combination with bortezomib plus dexamethasone (D-Vd) or lenalidomide plus dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of the phase 3 CASTOR and POLLUX studies in patients (pts) with early or late relapse after initial therapy
    Meeting Abstract

    Spencer, A.; Moreau, P.; Mateos, M. V.; Goldschmidt, H.; Suzuki, K.; Levin, M. D.; Sonneveld, P.; Yoon, S. S.; Usmani, S. Z.; Weisel, K.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase 1/2 study of the highly selective EGFR inhibitor, BLU-701, in patients with EGFR-mutant non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Spira, A. I.; Spigel, D. R.; Camidge, D. R.; De Langen, A.; Kim, T. M.; Goto, K.; Elamin, Y. Y.; Shum, E.; Reckamp, K. L.; Rotow, J. K.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase 1/2 study of BLU-451, a central nervous system (CNS) penetrant, small molecule inhibitor of EGFR, in incurable advanced cancers with EGFR exon 20 insertion (ex20ins) mutations
    Meeting Abstract

    Spira, A. I.; Yu, H. A.; Sun, L.; Nguyen, D.; Pearson, P.; Shim-Lopez, J.; Hausman, D. F.; Le, X.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Targeting insulin feedback to enhance alpelisib (TIFA): A phase II randomized trial in metastatic, PIK3CA-mutant, hormone receptor-positive breast cancer
    Meeting Abstract

    Shen, S.; Salehi, E.; Farooki, A.; Flory, J.; Williams, D.; Carpio, A.; Chang, C.; Lacouture, M. E.; Andreopoulou, E.; Sardesai, S. D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save